Midatech Pharma Plc: Commencement of First in Human Immunotherapy Study Using Gold Nanoparticle Technology
September 30 2016 - 7:11AM
Midatech Pharma PLC ("Midatech" or the
"Company")
Commencement of First in Human Immunotherapy
Study Using Gold Nanoparticle Technology
Midatech (AIM: MTPH; Nasdaq: MTP), the international specialty
pharmaceutical company focused on commercialising and developing
products in oncology, immunology and other therapeutic areas, today
announces that its first in human Phase I study of an innovative
vaccine (MTX102) using its gold nanoparticle (GNP) technology in
type 1 diabetes has commenced. The results from the study are
expected in 2017. The nano-vaccine approach also has potential
applicability in oncology.
The MTX102 vaccine uses Midatech's primary
platform GNP technology. GNPs are inert and chemically bound to
small antigens which generate a tolerogenic response when injected
into the skin, turning down the immune response against the insulin
producing cells which cause type 1 diabetes. This is the first
investigational product of its type to be used in humans.
The Phase I study of eight subjects aged 16-40
years with type 1 diabetes and residual endogenous insulin
production aims to examine the general safety and tolerability of
treatment. Secondary objectives are to study the feasibility of
delivering GNP via microneedles and the scale and nature of immune
responses generated in the body. The trial, conducted at two
centres (Cardiff, UK and Linköping, Sweden), is the culmination of
a four-year European Commission-supported program EE-ASI into
researching beta cell preservation using Antigen Specific
Immunotherapy (ASI) via GNP technology (www.ee-asi.eu).
Commenting on the announcement, Dr Jim
Phillips, CEO of Midatech, said: "I am pleased to be able to
announce the start of this important Phase I study which uses our
GNP technology in an immunotherapy. We are hopeful that this trial
will demonstrate the broad applicability of our technology and is
exciting for the future of our R&D pipeline. We are pleased to
be performing this study with support by a European Commission
grant, and look forward to updating the market with results in
2017."
ENDS
For more information, please contact:
Midatech Pharma PLC Jim Phillips, CEO
Tel: +44 (0)1235 888300 www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated
Adviser and Broker) Corporate Finance Freddy Crossley
Duncan Monteith Corporate Broking Tom Salvesen Tel: +44
(0)20 7886 2500
Consilium Strategic Communications (Financial
PR) Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik
Thys Tel: +44 (0)20 3709 5700 Email:
midatech@consilium-comms.com
Westwicke Partners (US Investor
Relations) Chris Brinzey Tel: +1 339 970 2843 Email:
chris.brinzey@westwicke.com
About Midatech Pharma PLC Midatech is an
international specialty pharmaceutical company focused on oncology
and other therapeutic areas with a commercial platform and four
marketed products in the US. Midatech's strategy is to develop
products in-house in oncology and with partners in other
indications, and to accelerate growth organically and through
strategic acquisitions. The Company's R&D activities are
supported by two breakthrough drug delivery technologies. The
Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in
four countries. For further company information see:
www.midatechpharma.com
About our gold nanoparticle (GNP)
technology The patented gold nanoparticle (GNP) technology has
been developed to improve key parameters when bound to existing and
new drugs. GNPs comprise of a core of gold metal atoms to which an
organic layer of carbohydrates or glycans (e.g. glucose, galactose
or lactose) are attached via gold-sulphur bonds. Linkers for
therapeutic agents (e.g. small molecules and chemotherapeutics) and
peptides (e.g. insulin) - are attached to the gold core during the
self-formation process. This process involves intricate yet
uncomplicated synthesis that produces multi-component particles
that may deliver multiple drug molecules to the targeted site. The
GNP platform has potential uses in Oncology, Immunology/
Auto-immunology and Neurology, amongst others.
Forward-Looking Statement Certain
statements in this press release may constitute "forward-looking
statements" within the meaning of legislation in the United Kingdom
and/or United States. Such forward-looking statements include, but
are not limited to, statements regarding the ability of Midatech to
successfully test, manufacture, produce or commercialize products
for conditions using the nanoparticle and sustained release drug
delivery platforms, and the ability for products in development to
achieve positive clinical results, and the ability to meet or
achieve timelines associated with pre-clinical studies, clinical
trials or regulatory submissions. Any forward-looking statements
are based on currently available competitive, financial and
economic data together with management's views and assumptions
regarding future events and business performance as of the time the
statements are made and are subject to risks and uncertainties. We
wish to caution you that there are some known and unknown factors
that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by
such forward-looking statements.
Reference should be made to those documents that
Midatech shall file from time to time or announcements that may be
made by Midatech in accordance with the London Stock Exchange AIM
Rules for Companies ("AIM Rules"), the Disclosure and Transparency
Rules ("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Sep 2023 to Sep 2024